<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00754208</url>
  </required_header>
  <id_info>
    <org_study_id>380-08</org_study_id>
    <nct_id>NCT00754208</nct_id>
  </id_info>
  <brief_title>Long Acting Stimulant Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Young Children</brief_title>
  <official_title>Long Acting Stimulant Treatment of ADHD in Young Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study evaluating the effectiveness, safety, and tolerability of Ritalin LA in&#xD;
      treating Attention Deficit Hyperactivity Disorder (ADHD) in 4 and 5 year old children.&#xD;
      Virtually no data has been published on the use of long-acting stimulant preparations in very&#xD;
      young children despite early symptomatic development in a significant portion of young&#xD;
      children with ADHD. This would be one of the first studies looking at a long-acting&#xD;
      preparation of a stimulant medication in the treatment of ADHD in very young children.&#xD;
&#xD;
      Hypotheses&#xD;
&#xD;
        1. Ritalin LA is effective for the treatment of ADHD in 4 and 5 year old children.&#xD;
&#xD;
        2. Ritalin LA is reasonably well-tolerated in the treatment of ADHD in 4 and 5 year old&#xD;
           children.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol involves an 8-week, open-label, pilot study evaluating the effectiveness,&#xD;
      safety, and tolerability of Ritalin LA in treating Attention-Deficit/Hyperactivity Disorder&#xD;
      (ADHD) in 4 and 5 year old children. The purpose of this study is to ascertain pilot data on&#xD;
      the use of long-acting stimulants in preschool-age children since virtually no data exist on&#xD;
      these medications in this population. The interventions include utilizing short-acting&#xD;
      methylphenidate for the initial dosing and titration and then converting the children to&#xD;
      Ritalin LA once an optimal dose has been found. Parents will also be receiving parent&#xD;
      education training throughout the study. Evaluations will include obtaining the ADHD-IV at&#xD;
      every visit, side effects of the medication, vital signs, EKG, physical exam, the Clinical&#xD;
      Global Assessment Scale, and the Clinical Global Impression-Improvement and Severity Scales.&#xD;
      This study will also assess parent stress with the Parent Stress Index and the emotional&#xD;
      index of the children with the Expressed Emotion Scale for Children. Follow-up will be weekly&#xD;
      during the first month and bi-weekly during the second month.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Attention Deficit Hyperactivity Disorder Rating Scale-IV Parent Version Investigator-Scored (ADHD-IV-Parent: Inv) Total Score.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change from baseline to endpoint of investigator-scored, parent version of the Attention Deficit Hyperactivity Disorder Rating Scale-IV (ADHD-IV rating scale). The ADHD-IV contains 18 items, and each item is rated 0, 1, 2 or 3. Minimum score is 0. Maximum score is 54. Change in score represents the difference between the total score at end point compared to the total score at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Global Impression-Severity</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in global rating of severity of ADHD symptoms. CGI severity is rated on a scale of 1 to 6 (normal to severely ill; refer to description in baseline information). The change in the severity rating reflects the change in this score from baseline to endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Children's Global Assessment Scale (CGAS) Score</measure>
    <time_frame>8 weeks</time_frame>
    <description>This measures the change in the subject's global assessment of functioning as rated by the clinician. This Children's Global Assessment Scale (CGAS) is rated on a 0-100 scale (refer to baseline information). The change in this score is the difference between the score at baseline to end point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression- Improvement</measure>
    <time_frame>8 weeks</time_frame>
    <description>The Clinical Global Impression-Improvement scale is a measure of the clinician's assessment of the overall degree of improvement in ADHD symptoms from baseline to endpoint. The CGI-I is rated on a 1 to 6 scale, with 1=very much improved, 2=much improved, 3=minimally improved, 4= no change, 5= minimally worse, 6=much worse.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>methylpehnidate</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>open-label treatment with methylphenidate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylphenidate</intervention_name>
    <description>Starting dose: methylphenidate (immediate-release pill) or Methylin (immediate-release chewable tablet for those unable to swallow pills) 2.5mg Q AM and Q noon. Target dose of 1mg/kg/day. Titration will occur as follows: 5mg Q AM and Q noon, then 7.5mg Q AM and Q noon, then 10mg Q AM and Q noon, as tolerated, not to exceed 30mg per day. Once each child arrives at a stable dose with a good response and good tolerability, they will be converted to the closest Ritalin LA dose, with a target dose of 1mg/kg/day.</description>
    <arm_group_label>methylpehnidate</arm_group_label>
    <other_name>Ritalin</other_name>
    <other_name>Methylin</other_name>
    <other_name>Ritalin LA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent obtained from the legal guardian.&#xD;
&#xD;
          -  Parent and child must be English-speaking.&#xD;
&#xD;
          -  The child must have been living with the parent or guardian for a minimum of 6 months&#xD;
             at the time of study entry.&#xD;
&#xD;
          -  Age: 4-5 years of age at study entry.&#xD;
&#xD;
          -  weight of at least 15kg (20th percentile for 4 year olds) for boys and weight of at&#xD;
             least 14.5kg (20th percentile for 4 year olds) for girls&#xD;
&#xD;
          -  Severity: age and sex-adjusted T score greater or equal to 65 on the Hyperactive-&#xD;
             Impulsive Subscale of both the Conners Parent and Teacher Rating Scales (L)&#xD;
&#xD;
          -  Diagnosis: meets DSM-IV criteria for ADHD (hyperactive/impulsive or combined subtype),&#xD;
             on Parent Diagnostic Interview Schedule for Children-IV (DISC-IV) and clinical&#xD;
             interview by experienced clinician. ADHD must be the primary disorder.&#xD;
&#xD;
          -  Duration: symptoms must have been present for a minimum of nine months.&#xD;
&#xD;
          -  Impairment: less than or equal to 55 on the Child Global Assessment Scale.&#xD;
&#xD;
          -  Cognitive functioning: An estimated IQ 70 or greater on the Peabody Picture Vocabulary&#xD;
             Test (PPVT).&#xD;
&#xD;
          -  School: participation in school-type program at least 2 half-days per week where class&#xD;
             includes at least 8 peers; if child has been expelled from an eligible program in the&#xD;
             3 months before screening, they can be considered for enrollment as this may reflect&#xD;
             severity of the disorder&#xD;
&#xD;
          -  Parents and patients must be able to attend regular study visits.&#xD;
&#xD;
          -  Children being treated with other stimulant or non-stimulant medications prior to&#xD;
             enrollment will be allowed to discontinue treatment with these medications in order to&#xD;
             enter the study, providing the parent wants to do so to enable their child to have a&#xD;
             trial of Ritalin LA, the target symptoms are not well-controlled or unwanted side&#xD;
             effects are persisting on their current treatment, and the prescribing physician is&#xD;
             notified by the parent. These children will have a visit 1A in order to accommodate a&#xD;
             5 half-lives washout of their pre-study medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other medications: no concurrent psychotropic medications or other medications&#xD;
             (including herbal preparations and over-the-counter medications) with significant CNS&#xD;
             effects (e.g., antidepressants, antipsychotics, drugs affecting blood pressure or&#xD;
             heart rate, anticonvulsants, alpha-agonists, adrenergic blockers, lithium, or sedating&#xD;
             antihistamines).&#xD;
&#xD;
          -  General medical conditions: children with major medical conditions that would&#xD;
             interfere with involvement in the study or the study medication will not be enrolled.&#xD;
&#xD;
          -  Serious structural cardiac abnormalities: The recent joint advisory of the American&#xD;
             Academy of Pediatrics (AAP) and the American Heart Association (AHA) recommend use of&#xD;
             stimulant medications should generally be avoided in patients with cardiomyopathy,&#xD;
             serious heart rhythm or structural abnormalities, or other serious cardiac problems.&#xD;
             Any patient with such a diagnosis will not be allowed in this study.&#xD;
&#xD;
          -  Systolic and diastolic blood pressure above 95th percentile for age and gender&#xD;
&#xD;
          -  Exclusionary Psychiatric Conditions: Current Adjustment Disorder, Autism, Psychosis,&#xD;
             Bipolar Disorder, PTSD, significant suicidality, or any other psychiatric disorder in&#xD;
             addition to ADHD that requires treatment with additional medications.&#xD;
&#xD;
          -  History of physical, sexual, or emotional abuse that results in a clinically&#xD;
             significant impact on clinical presentation, potentially driving some of the symptoms&#xD;
             of ADHD.&#xD;
&#xD;
          -  Prior failure to respond to an adequate trial of any methylphenidate product. This&#xD;
             will be at the determination of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joan Daughton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-5584</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>September 15, 2008</study_first_submitted>
  <study_first_submitted_qc>September 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2008</study_first_posted>
  <results_first_submitted>December 19, 2017</results_first_submitted>
  <results_first_submitted_qc>February 20, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 22, 2018</results_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Joan Daughton, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Attention Deficit Hyperactivity Disorder</keyword>
  <keyword>Stimulant Treatment</keyword>
  <keyword>Young Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment occurred from September 2008 through Deceber 2009 in an academic medical center.</recruitment_details>
      <pre_assignment_details>Please see inclusion and exclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ritalin LA for ADHD</title>
          <description>Subjects treated with Ritalin LA for ADHD</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ritalin LA for ADHD</title>
          <description>4 and 5 year old subjects with ADHD</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4" lower_limit="4" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Child and adolescent psychiatry clinic outpatients</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ADHD Subtype</title>
          <description>Diagnostic subtype identified on clinical interview and assessment of ADHD symptoms. There are a total of 18 symptoms of ADHD (9 inattentive and 9 hyperactive/impulsive). Subjects are identified as having combined subtype if &gt;/= 6/9 inattentive and &gt;/= 6/9 hyperactive/impulsive symptoms are endorsed. If only the inattentive criterion is met, subjects are identified as having inattentive subtype, and if only the hyperactive/impulsive criterion is met, subjects are identified as having hyperactive/impulsive subtype.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>ADHD, combined subtype</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ADHD, inattentive subtype</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ADHD, hyperactive/impulsive subtype</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Comorbid Oppositional Defiant Disorder</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>YES</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NO</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Treatment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Individual therapy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pharmacotherapy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No prior treatment</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Global Impression-Severity Score</title>
          <description>The CGI-S is the clinician's assessment of the subject's severity of illness based upon his/her knowledge and experience with the population and disorder under study. The CGI-S is rated on a scale of 1 to 6, with 1 representing &quot;normal, not ill&quot;, 2 representing &quot;borderline ill&quot;, 3 representing &quot;mildly ill&quot;, 4 representing &quot;moderately ill&quot;, 5 representing &quot;markedly ill&quot;, and 6 representing &quot;severely ill.&quot;</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.14" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Children's Global Assessment Scale</title>
          <description>The children's global assessment scale is the clinician's assessment of the subject's level of functioning as rated from 0 to 100 (worst to best).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.9" spread="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Attention Deficit Hyperactivity Disorder Rating Scale-IV Parent Version Investigator-Scored (ADHD-IV-Parent: Inv) Total Score.</title>
        <description>Change from baseline to endpoint of investigator-scored, parent version of the Attention Deficit Hyperactivity Disorder Rating Scale-IV (ADHD-IV rating scale). The ADHD-IV contains 18 items, and each item is rated 0, 1, 2 or 3. Minimum score is 0. Maximum score is 54. Change in score represents the difference between the total score at end point compared to the total score at baseline.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>All subjects treated with open-label methylphenidate (Ritalin LA)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Attention Deficit Hyperactivity Disorder Rating Scale-IV Parent Version Investigator-Scored (ADHD-IV-Parent: Inv) Total Score.</title>
          <description>Change from baseline to endpoint of investigator-scored, parent version of the Attention Deficit Hyperactivity Disorder Rating Scale-IV (ADHD-IV rating scale). The ADHD-IV contains 18 items, and each item is rated 0, 1, 2 or 3. Minimum score is 0. Maximum score is 54. Change in score represents the difference between the total score at end point compared to the total score at baseline.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.1" spread="13.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Clinical Global Impression-Severity</title>
        <description>Change in global rating of severity of ADHD symptoms. CGI severity is rated on a scale of 1 to 6 (normal to severely ill; refer to description in baseline information). The change in the severity rating reflects the change in this score from baseline to endpoint.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>All subjects treated with open-label methylphenidate</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Clinical Global Impression-Severity</title>
          <description>Change in global rating of severity of ADHD symptoms. CGI severity is rated on a scale of 1 to 6 (normal to severely ill; refer to description in baseline information). The change in the severity rating reflects the change in this score from baseline to endpoint.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Children's Global Assessment Scale (CGAS) Score</title>
        <description>This measures the change in the subject's global assessment of functioning as rated by the clinician. This Children's Global Assessment Scale (CGAS) is rated on a 0-100 scale (refer to baseline information). The change in this score is the difference between the score at baseline to end point.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>All subjects treated with open-label methylphenidate</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Children's Global Assessment Scale (CGAS) Score</title>
          <description>This measures the change in the subject's global assessment of functioning as rated by the clinician. This Children's Global Assessment Scale (CGAS) is rated on a 0-100 scale (refer to baseline information). The change in this score is the difference between the score at baseline to end point.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" spread="6.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression- Improvement</title>
        <description>The Clinical Global Impression-Improvement scale is a measure of the clinician's assessment of the overall degree of improvement in ADHD symptoms from baseline to endpoint. The CGI-I is rated on a 1 to 6 scale, with 1=very much improved, 2=much improved, 3=minimally improved, 4= no change, 5= minimally worse, 6=much worse.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>All subjects treated with open-label methylphenidate</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression- Improvement</title>
          <description>The Clinical Global Impression-Improvement scale is a measure of the clinician's assessment of the overall degree of improvement in ADHD symptoms from baseline to endpoint. The CGI-I is rated on a 1 to 6 scale, with 1=very much improved, 2=much improved, 3=minimally improved, 4= no change, 5= minimally worse, 6=much worse.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Very Much Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Much Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Minimally Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Minimally Worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Much Worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <desc>Adverse events were collected by spontaneous report</desc>
      <group_list>
        <group group_id="E1">
          <title>Methylpehnidate</title>
          <description>open-label treatment with methylphenidate&#xD;
methylphenidate: Starting dose: methylphenidate (immediate-release pill) or Methylin (immediate-release chewable tablet for those unable to swallow pills) 2.5mg Q AM and Q noon. Target dose of 1mg/kg/day. Titration will occur as follows: 5mg Q AM and Q noon, then 7.5mg Q AM and Q noon, then 10mg Q AM and Q noon, as tolerated, not to exceed 30mg per day. Once each child arrives at a stable dose with a good response and good tolerability, they will be converted to the closest Ritalin LA dose, with a target dose of 1mg/kg/day.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nail biting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tics</sub_title>
                <description>eye muscle disturbance; tongue movements</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study is limited by a small sample size and open-label design.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Joan Daughton, MD</name_or_title>
      <organization>University of Nebrasa Medical Center</organization>
      <phone>4025526006</phone>
      <email>jdaughton@childrensomaha.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

